Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005002 · ClinicalTrials.gov registry record · Phase 1
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03005002 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT03005002, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Durvalumab
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005002
The ClinicalTrials.gov registry entry for NCT03005002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT03005002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03005002 about?
NCT03005002 is a clinical study titled "Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver". This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells t...
What is the current status of trial NCT03005002?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-06-28. Estimated completion is 2019-11-26.
What interventions are being tested in trial NCT03005002?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03005002?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.